Skip to main content

Table 2 Number of patients, antihypertensive prescriptions and baseline ACEIs prescription proportion in the 13 UK regions

From: The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Regions

Baseline ACEIs prescription proportion (%)

ACEIs prescription proportion (%) at the end of the study

Total number of prescriptions

Total number of patients

High baseline ACEIs prescription proportion (>74 %)

  North East

80.8

74.2

1,143,760

13,319

  South East

74.7

71.6

3,865,373

53,299

  Wales

74.4

74.1

6,185,924

63,467

  East Midlands

74.3

75.8

1,364,324

22,370

Intermediate baselineACEIs prescription proportion (65 %-74 %)

  Yorkshire and the Humber

73.5

73.6

1,554,143

20,968

  East of England

72.5

72.1

3,505,910

52,733

  South Central

71.7

70.9

5,030,800

69,175

  Scotland

72.2

70.8

3,760,187

62,610

  West Midlands

69.5

68.5

3,764,019

52,920

  North West

69.2

70.8

6,279,440

80,575

  London

69.1

70.9

3,401,591

57,108

Low baseline ACEIs prescription proportion (<65 %)

  South East Coast

63.6

63.8

3,698,109

52,221

  Northern Ireland

60.3

65.5

801,164

15,256

  1. ACEIs Angiotensin converting enzyme inhibitors